Key result
Future drug treatments for diabetic dyslipidaemia will increasingly target mechanisms to improve glucose, LDL cholesterol, atherogenesis, and vascular risk.
Why the study?
Dyslipidaemia is a major risk factor for atherosclerotic coronary heart disease, the leading cause of mortality in type 2 diabetes, necessitating appropriate management strategies.
This review highlights the importance of multifactorial management, including lifestyle and drug interventions, for atherogenic dyslipidaemia in type 2 diabetes to reduce cardiovascular risk.
Answers are grounded in this paper and cite their sources.
Supports multifactorial targeting in diabetic dyslipidaemia; leaves open validation of specific agents in outcome trials.
Dyslipidaemia is a major risk factor for atherosclerotic coronary heart disease, which in turn is the commonest cause of mortality in type 2 diabetes. This highlights the importance of appropriate management of diabetic dyslipidaemia. Management is typically multifactorial and includes dietary recommendations, routine physical exercise, aggressive control of other lifestyle risk factors, and for many patients drug intervention. Future drug treatments will increasingly target not only mechanisms that might improve glucose and LDL cholesterol blood levels, but also improve other facets of diabetic dyslipidaemia, atherogenesis and vascular risk.
No takes yet. Share an insight, caveat, or question.
Harold Edward Bays (2003) conducted a review in Atherogenic dyslipidaemia in type 2 diabetes and metabolic syndrome. Management of diabetic dyslipidaemia was evaluated. Future drug treatments for diabetic dyslipidaemia will increasingly target mechanisms to improve glucose, LDL cholesterol, atherogenesis, and vascular risk.
Synapse has enriched 10 related papers. Consider them for comparative context: